Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09, Zacks reports.

Neumora Therapeutics Trading Down 9.9 %

NMRA stock traded down $0.16 during midday trading on Monday, hitting $1.41. 1,459,572 shares of the company's stock were exchanged, compared to its average volume of 4,350,463. The firm has a 50 day moving average price of $3.20 and a 200-day moving average price of $8.88. Neumora Therapeutics has a 12-month low of $1.40 and a 12-month high of $21.00. The stock has a market capitalization of $226.99 million, a price-to-earnings ratio of -0.75 and a beta of 2.50.

Wall Street Analyst Weigh In

NMRA has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of Neumora Therapeutics in a research report on Friday, February 14th. William Blair reiterated an "outperform" rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Bank of America lowered their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating for the company in a report on Monday, January 6th. Royal Bank of Canada downgraded shares of Neumora Therapeutics from an "outperform" rating to a "sector perform" rating and cut their price target for the stock from $29.00 to $4.00 in a research note on Thursday, January 2nd. Finally, JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $16.50.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.